Adoptive cell therapy market

Adoptive Cell Therapy Market, by Type (CAR-T, TCR-T, NK, and TIL), By Application (Lymphoma, Leukemia, and Others), by End User (Hospitals and Cancer Treatment Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Mar 2022
CMI4957
186 Pages
Excel & Pdf
Pharmaceutical

Summary

Adoptive cell therapy (ACT) is a kind of immunotherapy, in which T cells are genetically modified to express a chimeric antigen receptor (CAR) or T cell receptor (TCR). Adoptive cell therapy has made a great difference in treating multiple types of tumors. Some approaches of ACT involve directly isolating body’s immune cells and simply expanding their numbers, whereas other approaches involve genetically engineering body’s immune cells (via gene therapy) to enhance cancer-fighting capabilities

The global adoptive cell therapy market is estimated to be valued at US$ 4,932.5 million in 2022 and is expected to exhibit a CAGR of 21.5% during the forecast period (2022-2030).

Figure 1. Global Adoptive Cell Therapy Market Share (%) in Terms of Value, By Application, 2022

Increasing product approvals is expected to drive the market growth during the forecast period.

The increasing product approvals for adoptive cell therapy is expected to drive the global adoptive cell therapy market growth over the forecast period. For instance, in February 13, 2022, Innovent Biologics, Inc., a world-class biopharmaceutical company, together with IASO Biotherapeutics, a clinical-stage biopharmaceutical company jointly announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) had formally granted Orphan Drug Designation (ODD) to company’s co-developed fully-human B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma.

Adoptive Cell Therapy Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 4,932.5 million
Historical Data for:	2017-2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	21.5%	2030 Value Projection:	US$ 23,440.7 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: CAR-T, TCR-T, NK, TIL By Application: Lymphoma, Leukemia, Others By End User: Hospitals, Cancer Treatment Centers
Companies covered:	Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs
Growth Drivers:	Increasing research and development for adoptive cell therapy Rising prevalence of cancer Increasing product approvals
Restraints & Challenges:	Side effect associated with adoptive cell therapy

Figure 2. Global Adoptive Cell Therapy Market Share (%), By Type, 2022

Rising prevalence of cancer is expected to drive the market growth during the forecast period

Rising prevalence of cancer is expected to drive the global adoptive cell therapy market growth during the forecast period. For instance, according to the data published by the National Cancer Institute stated that there were an estimated 459,058 people living with leukemia in the U.S. in 2018.

Global Adoptive Cell Therapy Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 426 million infected individuals worldwide, as of February 23, 2022.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the global adoptive cell therapy market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing drug formulations due to irregularities in transportation. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening diseases. The coronavirus pandemic has negatively impacted the development, production, and supply of adoptive cell therapy products

Global Adoptive Cell Therapy Market: Restraint

The major factors that is expected to hinder growth of the global adoptive cell therapy market include side effects associated with adoptive cell therapy. Common side effects associated with adoptive cell therapies may include but are not limited to acute kidney injury, bleeding episodes, heart arrhythmias, chills, constipation, cough, cytokine release syndrome (cytokine storm), decreased appetite, delirium, diarrhea, dizziness, and others.

Key Players

Major players operating in the global adoptive cell therapy market include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs.

Table of Content

*Browse 29 market data tables and 33 figures on "Global Adoptive Cell Therapy Market” - Forecast to 2030

Segmentation

Detailed Segmentation:

Global Adoptive Cell Therapy Market, By Type :
- CAR-T
- TCR-T
- NK
- TIL
Global Adoptive Cell Therapy Market, By Application :
- Lymphoma
- Leukemia
- Others
Global Adoptive Cell Therapy Market, By End User :
- Hospitals
- Cancer Treatment Centers
Global Adoptive Cell Therapy Market, By Region:
- North America
  - By Type
    - CAR-T
    - TCR-T
    - NK
    - TIL
  - By Application
    - Lymphoma
    - Leukemia
    - Others
  - By End User
    - Hospital
    - Cancer Treatment Centers
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Type
    - CAR-T
    - TCR-T
    - NK
    - TIL
  - By Application
    - Lymphoma
    - Leukemia
    - Others
  - By End User
    - Hospital
    - Cancer Treatment Centers
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Type
    - CAR-T
    - TCR-T
    - NK
    - TIL
  - By Application
    - Lymphoma
    - Leukemia
    - Others
  - By End User
    - Hospital
    - Cancer Treatment Centers
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Type
    - CAR-T
    - TCR-T
    - NK
    - TIL
  - By Application
    - Lymphoma
    - Leukemia
    - Others
  - By End User
    - Hospital
    - Cancer Treatment Centers
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Type
    - CAR-T
    - TCR-T
    - NK
    - TIL
  - By Application
    - Lymphoma
    - Leukemia
    - Others
  - By End User
    - Hospital
    - Cancer Treatment Centers
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Type
    - CAR-T
    - TCR-T
    - NK
    - TIL
  - By Application
    - Lymphoma
    - Leukemia
    - Others
  - By End User
    - Hospital
    - Cancer Treatment Centers
  - By Country/Region
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global adoptive cell therapy market during the forecast period (2022-2030)?

The global adoptive cell therapy market size is estimated to be valued at US$ 4,932.5 million in 2022 and is expected to exhibit a CAGR of 21.5% between 2022 and 2030

What are the major factors driving the market growth?

Factors such as increasing research and development for adoptive cell therapy, rising prevalence of cancer, and increasing product approvals are expected to drive the market growth over forecast period.

Which is the leading type segment in the market?

Lymphoma segment is expected to hold a major market share in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include side effects associated with adoptive cell therapy.

Which are the major players operating in the market?

Major players operating in the market are Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs.